8月18日，昊海生科获东吴证券买入评级，近一个月昊海生科获得1份研报关注。
研报预计维持预计2024-2026年公司归母净利润分别为5.11亿元、6.32亿元、7.61亿元。研报认为，鉴于公司医美产品高速增长，眼科消化集采后有望恢复，因此做出了“买入”的评级。
风险提示：产品研发或推广不及预期的风险，市场竞争加剧风险等。
- Headlines
- 昊海生科获东吴证券买入评级，玻尿酸保持同比高增态势，扣非利润实现稳健增长
昊海生科获东吴证券买入评级，玻尿酸保持同比高增态势，扣非利润实现稳健增长
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Latest
16:44
The South Korean prosecution issued a summons request to Yoon Suk-yeol on the 15th.
16:40
Report: More than half of the respondents are willing to live in a retirement home, with a monthly payment of no more than 3000 yuan.
16:34
Report: Nearly 70% of respondents believe that the wealth required for Retirement is within 1 million.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.